Literature DB >> 28647738

Outcome and Treatment of Antenatally Diagnosed Nonimmune Hydrops Fetalis.

Ahmed A Nassr1, Amen Ness, Pardis Hosseinzadeh, Bahram Salmanian, Jimmy Espinoza, Victoria Berger, Eleonore Werner, Hadi Erfani, Stephen Welty, Zhoobin H Bateni, Amir A Shamshirsaz, Edwina Popek, Rodrigo Ruano, Alexis S Davis, Timothy C Lee, Sundeep Keswani, Darrell L Cass, Oluyinka O Olutoye, Michael A Belfort, Alireza A Shamshirsaz.   

Abstract

INTRODUCTION: The objectives of this study were to evaluate the outcome of nonimmune hydrops fetalis in an attempt to identify independent predictors of perinatal mortality.
MATERIAL AND METHODS: A retrospective cohort study was conducted including all cases of nonimmune hydrops from two tertiary care centers. Perinatal outcome was evaluated after classifying nonimmune hydrops into ten etiological groups. We examined the effect of etiology, site of fluid accumulation, and gestational age at delivery on postnatal survival. Neonatal mortality and hospital discharge survival were compared between the expectant management and fetal intervention groups among those with idiopathic etiology.
RESULTS: A total of 142 subjects were available for analysis. Generally, nonimmune hydrops carried 37% risk of neonatal mortality and 50% chance of survival to discharge, which varies markedly based on the underlying etiology. Ascites was an independent predictor of perinatal mortality (p value = 0.003). There was nonsignificant difference in neonatal mortality and hospital discharge survival among idiopathic cases that were managed expectantly versus those in whom fetal intervention was carried out. DISCUSSION: The outcome of nonimmune hydrops varies largely according to the underlying etiology and the presence of ascites is an independent risk factor for perinatal mortality. In our series, fetal intervention did not offer survival advantage among fetuses with idiopathic nonimmune hydrops.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Fetal ascites; Fetal hydrops; Fetal intervention; Fetal pleural effusion ; Neonatal mortality; Perinatal mortality; Survival

Mesh:

Year:  2017        PMID: 28647738     DOI: 10.1159/000475990

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  7 in total

Review 1.  A system-based approach to the genetic etiologies of non-immune hydrops fetalis.

Authors:  Anne H Mardy; Shilpa P Chetty; Mary E Norton; Teresa N Sparks
Journal:  Prenat Diagn       Date:  2019-06-26       Impact factor: 3.050

2.  [Whole exome sequencing analysis of compound heterozygous variants of CDAN1 gene in a Chinese family with non-immune hydrops fetalis].

Authors:  Y Wang; Q Li; X Sun; S Li; J He; M Zhang; L Huang; W He
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-12-20

3.  Frequency and Prognosis of Hydrops Fetalis: A 10-Year Single-Center Experience.

Authors:  Ebru Turkoglu Unal; Ali Bulbul; Evrim Kiray Bas; Hasan Sinan Uslu
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2021-09-24

4.  Clinical Course and Outcome of Non-Immune Fetal Hydrops in Singleton Pregnancies.

Authors:  Theresa Reischer; Bernadette Muth; Anja Catic; Cécile Monod; Tina Linder; Christian Göbl; Gülen Yerlikaya-Schatten
Journal:  J Clin Med       Date:  2022-01-28       Impact factor: 4.241

5.  Survival of Hydrops Fetalis with and without Fetal Intervention.

Authors:  Yu-Yun Huang; Yu-Jun Chang; Lih-Ju Chen; Cheng-Han Lee; Hsiao-Neng Chen; Jia-Yuh Chen; Ming Chen; Chien-Chou Hsiao
Journal:  Children (Basel)       Date:  2022-04-08

6.  Isolated non-immune hydrops fetalis: an observational study on complete spontaneous resolution, perinatal outcome, and long-term follow-up.

Authors:  Sophie Neveling; Alexander Johannes Knippel; Peter Kozlowski
Journal:  Arch Gynecol Obstet       Date:  2022-08-22       Impact factor: 2.493

Review 7.  SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review.

Authors:  Kavita Narang; Elizabeth Ann L Enninga; Madugodaralalage D S K Gunaratne; Eniola R Ibirogba; Ayssa Teles A Trad; Amro Elrefaei; Regan N Theiler; Rodrigo Ruano; Linda M Szymanski; Rana Chakraborty; Vesna D Garovic
Journal:  Mayo Clin Proc       Date:  2020-05-30       Impact factor: 7.616

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.